Which adults develop side-effects of growth hormone replacement?

Holmes SJ, Shalet SM

Clinical endocrinology1 Aug 1995Cited by 53 (Europe PMC)

PMID7554308DOI10.1111/j.1365-2265.1995.tb01908.xPepBankPUB-07554308

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialSafety outcome
In adults with GH deficiency, 25 patients (40%) developed no side-effects during GH replacement.
In plain wordsIn adults with GH deficiency, 25 patients (40%) had no side-effects during GH replacement.
Peptide
HGH (somatotropin)
Outcome
Not applicableNo side-effects
Study
n = 63
Outcome group
Adverse events · Whole body
Studied dose
0.125 IU/kg/week first month, then 0.25 IU/kg/week · 12 monthsAs given in this study (human).
Measurements
Patients with no side-effects
25 patients
GH replacement, 63 adults
Patients with no side-effects
40%
GH replacement, 63 adults
Source sentences
Summary
Twenty-five patients (40%) did not develop side-effects, 19 patients (30%) developed side-effects which did not necessitate a reduction in dose of GH, and 19 patients (30%) required a reduction in dose of GH because of side-effects.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month study (double blind placebo controlled for the first 6 months and open for the second 6 months) of GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) in adults.
Summary · context
Sixty-three adults (27 men, 36 women, aged 34.9 +/- 1.4 (mean +/- SE, range 20.1-59.5 years)) with GH deficiency (peak serum GH response to provocative testing of less than 10 mU/l) who took part in a 12-month study of GH replacement.
Report a problemFND-0755430801
02HumanNon-randomized trialSafety outcome
In adults with GH deficiency, 19 patients (30%) developed side-effects without needing GH dose reduction.
In plain wordsIn adults with GH deficiency, 19 patients (30%) had side-effects without needing a lower GH dose.
Peptide
HGH (somatotropin)
Outcome
Not applicableSide-effects without dose reduction
Study
n = 63
Outcome group
Adverse events · Whole body
Studied dose
0.125 IU/kg/week first month, then 0.25 IU/kg/week · 12 monthsAs given in this study (human).
Measurements
Patients with side-effects not needing dose reduction
19 patients
GH replacement, 63 adults
Patients with side-effects not needing dose reduction
30%
GH replacement, 63 adults
Source sentences
Summary
Twenty-five patients (40%) did not develop side-effects, 19 patients (30%) developed side-effects which did not necessitate a reduction in dose of GH, and 19 patients (30%) required a reduction in dose of GH because of side-effects.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month study (double blind placebo controlled for the first 6 months and open for the second 6 months) of GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) in adults.
Summary · context
Sixty-three adults (27 men, 36 women, aged 34.9 +/- 1.4 (mean +/- SE, range 20.1-59.5 years)) with GH deficiency (peak serum GH response to provocative testing of less than 10 mU/l) who took part in a 12-month study of GH replacement.
Report a problemFND-0755430802
03HumanNon-randomized trialSafety outcome
In adults with GH deficiency, 19 patients (30%) required GH dose reduction because of side-effects.
In plain wordsIn adults with GH deficiency, 19 patients (30%) needed a lower GH dose because of side-effects.
Peptide
HGH (somatotropin)
Outcome
Not applicableSide-effects requiring dose reduction
Study
n = 63
Outcome group
Adverse events · Whole body
Studied dose
0.125 IU/kg/week first month, then 0.25 IU/kg/week · 12 monthsAs given in this study (human).
Measurements
Patients needing GH dose reduction for side-effects
19 patients
GH replacement, 63 adults
Patients needing GH dose reduction for side-effects
30%
GH replacement, 63 adults
Source sentences
Summary
Twenty-five patients (40%) did not develop side-effects, 19 patients (30%) developed side-effects which did not necessitate a reduction in dose of GH, and 19 patients (30%) required a reduction in dose of GH because of side-effects.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month study (double blind placebo controlled for the first 6 months and open for the second 6 months) of GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) in adults.
Summary · context
Sixty-three adults (27 men, 36 women, aged 34.9 +/- 1.4 (mean +/- SE, range 20.1-59.5 years)) with GH deficiency (peak serum GH response to provocative testing of less than 10 mU/l) who took part in a 12-month study of GH replacement.
Report a problemFND-0755430803
04HumanObservational studySafety outcome
In GH-treated adults, dose-limiting side-effects were linked to peak serum GH response greater than 1 mU/l (P = 0.005).
In plain wordsIn GH-treated adults, dose-limiting side-effects were linked to higher peak GH responses compared with patients without dose-limiting side-effects.
Peptide
HGH (somatotropin)
Outcome
IncreasePeak GH response and dose-limiting side-effects
Study
n: not reported in source
Comparator
Patients without side-effects or without dose reduction
Outcome group
Adverse events · Whole body
Studied dose
0.125 IU/kg/week first month, then 0.25 IU/kg/week · 12 monthsAs given in this study (human).
Measurements
Peak serum GH response cutoff
> 1 mU/l
dose-reduction group vs others
P value
0.005
dose-reduction group vs others, peak serum GH response above 1 mU/l
Source sentences
Summary
Those patients who required a reduction in dose of GH because of side-effects were more likely to have a peak serum GH response of greater than 1 mU/l (P = 0.005) and to have adult onset GH deficiency (P = 0.04) than those who did not develop side-effects or who did not require a reduction in dose o…
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month study (double blind placebo controlled for the first 6 months and open for the second 6 months) of GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) in adults.
Summary · context
Sixty-three adults (27 men, 36 women, aged 34.9 +/- 1.4 (mean +/- SE, range 20.1-59.5 years)) with GH deficiency (peak serum GH response to provocative testing of less than 10 mU/l) who took part in a 12-month study of GH replacement.
Report a problemFND-0755430804
05HumanObservational studySafety outcome
In GH-treated adults, dose-limiting side-effects were linked to adult onset GH deficiency (P = 0.04).
In plain wordsIn GH-treated adults, dose-limiting side-effects were linked to adult onset deficiency compared with patients without dose-limiting side-effects.
Peptide
HGH (somatotropin)
Outcome
IncreaseAdult onset deficiency and dose-limiting side-effects
Study
n: not reported in source
Comparator
Patients without side-effects or without dose reduction
Outcome group
Adverse events · Whole body
Studied dose
0.125 IU/kg/week first month, then 0.25 IU/kg/week · 12 monthsAs given in this study (human).
Measurements
P value
0.04
dose-reduction group vs others, adult onset GH deficiency
Source sentences
Summary
Those patients who required a reduction in dose of GH because of side-effects were more likely to have a peak serum GH response of greater than 1 mU/l (P = 0.005) and to have adult onset GH deficiency (P = 0.04) than those who did not develop side-effects or who did not require a reduction in dose o…
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month study (double blind placebo controlled for the first 6 months and open for the second 6 months) of GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) in adults.
Summary · context
Sixty-three adults (27 men, 36 women, aged 34.9 +/- 1.4 (mean +/- SE, range 20.1-59.5 years)) with GH deficiency (peak serum GH response to provocative testing of less than 10 mU/l) who took part in a 12-month study of GH replacement.
Report a problemFND-0755430805
06HumanObservational studySafety outcome
In GH-treated adults, dose-limiting side-effects were linked to older age compared with no side-effects (P = 0.002).
In plain wordsIn GH-treated adults, dose-limiting side-effects were linked to older age compared with patients without side-effects.
Peptide
HGH (somatotropin)
Outcome
IncreaseAge and dose-limiting side-effects
Study
n: not reported in source
Comparator
Patients without side-effects
Outcome group
Adverse events · Whole body
Studied dose
0.125 IU/kg/week first month, then 0.25 IU/kg/week · 12 monthsAs given in this study (human).
Measurements
P value
0.002
dose-reduction group vs no side-effects, age
Source sentences
Summary
In addition, those who needed a reduction in GH dose were older (P = 0.002), heavier (P = 0.04) and had a greater BMI (P = 0.003) than those who did not develop side-effects.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month study (double blind placebo controlled for the first 6 months and open for the second 6 months) of GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) in adults.
Summary · context
Sixty-three adults (27 men, 36 women, aged 34.9 +/- 1.4 (mean +/- SE, range 20.1-59.5 years)) with GH deficiency (peak serum GH response to provocative testing of less than 10 mU/l) who took part in a 12-month study of GH replacement.
Report a problemFND-0755430806
07HumanObservational studySafety outcome
In GH-treated adults, dose-limiting side-effects were linked to greater weight compared with no side-effects (P = 0.04).
In plain wordsIn GH-treated adults, dose-limiting side-effects were linked to greater weight compared with patients without side-effects.
Peptide
HGH (somatotropin)
Outcome
IncreaseWeight and dose-limiting side-effects
Study
n: not reported in source
Comparator
Patients without side-effects
Outcome group
Adverse events · Whole body
Studied dose
0.125 IU/kg/week first month, then 0.25 IU/kg/week · 12 monthsAs given in this study (human).
Measurements
P value
0.04
dose-reduction group vs no side-effects, weight
Source sentences
Summary
In addition, those who needed a reduction in GH dose were older (P = 0.002), heavier (P = 0.04) and had a greater BMI (P = 0.003) than those who did not develop side-effects.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month study (double blind placebo controlled for the first 6 months and open for the second 6 months) of GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) in adults.
Summary · context
Sixty-three adults (27 men, 36 women, aged 34.9 +/- 1.4 (mean +/- SE, range 20.1-59.5 years)) with GH deficiency (peak serum GH response to provocative testing of less than 10 mU/l) who took part in a 12-month study of GH replacement.
Report a problemFND-0755430807
08HumanObservational studySafety outcome
In GH-treated adults, dose-limiting side-effects were linked to greater BMI compared with no side-effects (P = 0.003).
In plain wordsIn GH-treated adults, dose-limiting side-effects were linked to greater BMI compared with patients without side-effects.
Peptide
HGH (somatotropin)
Outcome
IncreaseBMI and dose-limiting side-effects
Study
n: not reported in source
Comparator
Patients without side-effects
Outcome group
Adverse events · Whole body
Studied dose
0.125 IU/kg/week first month, then 0.25 IU/kg/week · 12 monthsAs given in this study (human).
Measurements
P value
0.003
dose-reduction group vs no side-effects, BMI
Source sentences
Summary
In addition, those who needed a reduction in GH dose were older (P = 0.002), heavier (P = 0.04) and had a greater BMI (P = 0.003) than those who did not develop side-effects.
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month study (double blind placebo controlled for the first 6 months and open for the second 6 months) of GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) in adults.
Summary · context
Sixty-three adults (27 men, 36 women, aged 34.9 +/- 1.4 (mean +/- SE, range 20.1-59.5 years)) with GH deficiency (peak serum GH response to provocative testing of less than 10 mU/l) who took part in a 12-month study of GH replacement.
Report a problemFND-0755430808
09HumanObservational studySafety outcome
In GH-treated adults, side-effects without dose reduction were linked to greater IGF-I SDS increments than no side-effects (P = 0.03).
In plain wordsIn GH-treated adults, side-effects without dose reduction were linked to larger IGF-I SDS increases compared with patients without side-effects.
Peptide
HGH (somatotropin)
Outcome
IncreaseIGF-I SDS increment and side-effects
Study
n: not reported in source
Comparator
Patients without side-effects
Outcome group
Adverse events · Whole body
Studied dose
0.125 IU/kg/week first month, then 0.25 IU/kg/week · 6 monthsAs given in this study (human).
Measurements
P value
0.03
side-effects without dose reduction vs no side-effects, IGF-I SDS increment after 6 months
Source sentences
Summary
Those who developed side-effects but did not require a reduction in dose of GH had a greater increment in IGF-I SDS after 6 months of GH replacement than those who did not develop side-effects (P = 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
A 12-month study (double blind placebo controlled for the first 6 months and open for the second 6 months) of GH replacement (0.125 IU/kg/week for the first month and 0.25 IU/kg/week thereafter) in adults.
Summary · context
Sixty-three adults (27 men, 36 women, aged 34.9 +/- 1.4 (mean +/- SE, range 20.1-59.5 years)) with GH deficiency (peak serum GH response to provocative testing of less than 10 mU/l) who took part in a 12-month study of GH replacement.
Report a problemFND-0755430809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.